A Phase 2a Study of SUN-627 to Evaluate Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Impact on Measures of Neuroinflammation in the Central Nervous System in Participants With Non-Active Progressive Multiple Sclerosis (SPMS/PPMS)
Key facts
- Where
- Turku, FinnországSee the site
- Phase
- 2. fázis
Where in Finnország
- Turku University HospitalTurku, FinnországTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Sundance Biosciences Inc.
- Trial code
- EU 2026-525817-29-00
- Record updated
- 2026. november 5.
- Original description
To assess safety and tolerability of SUN-627Read full original descriptionShow less
To assess safety and tolerability of SUN-627
Inclusion: Aged 18-70, inclusive; Diagnosis of PPMS or non-active SPMS; No MS relapses in the past 2 years; Evidence that MS has continued to get worse over time; A level of disability that fits the study requirements; Additional inclusion criteria are outlined in the full study protocol.
Exclusion: Use of certain medications or treatments before the study, or need for these treatments during the study; Certain abnormal heart rhythm findings on ECG or other heart conditions that may increase risk; Certain serious or unstable medical conditions that could make the study unsafe; Active infection, recent infection, or a history of repeated infections; Current participation in another research study; Additional exclusion criteria are outlined in the full study protocol.